India Glycols Ltd Valuation Shifts to Fair Amidst Sector Comparisons

Valuation Metrics and Market Context

As of 17 Aug 2026, India Glycols trades at ₹1,070.10, up 1.47% from the previous close of ₹1,054.55. The stock’s 52-week range spans ₹793.95 to ₹1,222.85, indicating a recovery from lows but still shy of its peak. The company’s P/E ratio stands at 22.63, while its P/BV is 2.45, both marking a shift from previously more attractive levels to what MarketsMOJO now classifies as a 'fair' valuation grade. This reclassification was formalised on 14 Aug 2026, when the Mojo Grade was downgraded from Hold to Sell, with a current Mojo Score of 47.0.

These valuation changes come amid a backdrop of robust financial metrics: a return on capital employed (ROCE) of 10.80% and return on equity (ROE) of 10.00%, alongside a dividend yield of 1.13%. The enterprise value to EBITDA (EV/EBITDA) ratio is 13.17, which, while reasonable, is notably lower than many peers in the commodity chemicals space.

Peer Comparison Highlights Valuation Disparity

When benchmarked against key competitors, India Glycols’ valuation appears more moderate. Industry heavyweights such as Navin Fluorine International, Himadri Speciality Chemical, and Sumitomo Chemical trade at significantly higher P/E ratios of 53.19, 49.5, and 49.32 respectively, with EV/EBITDA multiples exceeding 34 in each case. Similarly, Acutaas Chemical and Aether Industries command P/E ratios above 68 and 90, underscoring their 'very expensive' valuation status.

Even other 'fairly' valued peers like Atul and Aarti Industries maintain P/E ratios of 24.92 and 37.18, respectively, slightly above India Glycols. This relative valuation gap suggests that while India Glycols is no longer considered undervalued, it remains more reasonably priced than many of its sector rivals.

Stock Performance Versus Sensex

India Glycols’ stock performance over various time horizons further contextualises its valuation. The company has delivered a 1-year return of 32.77%, significantly outperforming the Sensex’s negative 3.21% over the same period. Over three and five years, the stock has surged by approximately 195%, dwarfing the Sensex’s 19.28% and 40.72% gains respectively. The decade-long return is particularly striking at 2,172.94%, compared to the Sensex’s 177.10%.

However, short-term returns have been more volatile, with a 1-week decline of 6.48% and a 1-month drop of 2.89%, both underperforming the Sensex’s modest positive returns. This recent weakness may have contributed to the reassessment of valuation attractiveness.

Implications of Valuation Shift

The downgrade from an attractive to a fair valuation grade signals a more cautious stance from analysts and investors. The P/E ratio of 22.63, while not excessive, is elevated relative to historical levels for India Glycols, which had previously traded at more compelling multiples. The P/BV of 2.45 also reflects a premium to book value that may limit upside potential unless earnings growth accelerates.

Moreover, the PEG ratio of 1.13 suggests that the stock’s price is roughly in line with its earnings growth prospects, neither undervalued nor overvalued on this metric. This contrasts with some peers whose PEG ratios are either significantly lower or higher, indicating varying growth expectations and risk profiles.

Financial Quality and Operational Efficiency

India Glycols’ ROCE and ROE figures, both around 10%, indicate moderate efficiency in generating returns from capital and equity. While respectable, these returns are not markedly superior to industry averages, which may explain the tempered enthusiasm from the market. The dividend yield of 1.13% is modest, offering limited income appeal to yield-focused investors.

Enterprise value multiples such as EV/EBITDA at 13.17 and EV/EBIT at 17.43 further reinforce the fair valuation narrative. These multiples are significantly lower than those of 'very expensive' peers, suggesting that India Glycols may offer a more balanced risk-reward profile, albeit with less growth excitement.

Outlook and Investor Considerations

For investors, the shift in valuation grading from attractive to fair necessitates a more nuanced approach. While India Glycols has demonstrated strong long-term returns and maintains solid operational metrics, the current price levels reflect a market that is less willing to pay a premium without clear catalysts for accelerated growth.

Comparatively, the company’s valuation remains more reasonable than many of its commodity chemical peers, which trade at steep premiums. This relative affordability could appeal to value-oriented investors seeking exposure to the sector without the elevated risk associated with highly priced stocks.

However, the downgrade to a Sell grade by MarketsMOJO signals caution. Investors should closely monitor earnings trends, margin stability, and sector dynamics before committing fresh capital. The recent short-term underperformance relative to the Sensex also suggests potential volatility ahead.

Conclusion

India Glycols Ltd’s transition from an attractive to a fair valuation grade reflects evolving market sentiment amid a competitive and expensive peer landscape. While the company’s fundamentals remain sound, the current multiples indicate limited upside from a valuation perspective. Investors are advised to weigh the company’s solid long-term returns against the tempered growth outlook and peer valuations before making investment decisions.

Overall, India Glycols presents a balanced risk-reward profile in the commodity chemicals sector, with valuation metrics that have moderated in line with recent price action and market realities.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today